Charlotte Jenkins, 16, from Stockport in Greater Manchester battled against a rare form of acute myeloid leukaemia to be able to sit her GCSEs and go to her end of school prom.

Related Links:

Application of next-generation sequencing (NGS) panels is usually limited to diagnosis, prognosis, and development of personalized treatment strategies/targeted therapies for patients with myeloid malignancies e.g., Myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and acute myelogenous leukemia (AML). Here we present a case of 3 year old male that presented with pancytopenia and splenomegaly. His initial bone marrow revealed mild to moderate fibrosis (normocellular; no increase in blasts).

Source: Cancer Genetics and CytogeneticsCategory: Genetics & Stem Cells Authors: Source Type: research

Acute myeloid leukemia (AML) is grouped in multiple subtypes based on recurrent genomic abnormalities with diagnostic and prognostic significance. To enhance our diagnostic approach, we developed a clinical whole-genome mate pair-sequencing (MPseq) assay to detect structural rearrangements and copy number changes. DNA is processed using Illumina Nextera MP library kit, sequenced and aligned to the reference genome using BIMA. Abnormalities are visualized using Mayo-developed Ingenium software using AML-panel restricting analysis to classic-AML rearrangements: ABL1, BCR, CBFB, CREBBP, DEK, KAT6A, MECOM, MLF1, MLL(KMT2A), MY…

Source: Cancer Genetics and CytogeneticsCategory: Genetics & Stem Cells Authors: Source Type: research

Publication date: September 2018Source: Biochimica et Biophysica Acta (BBA) – General Subjects, Volume 1862, Issue 9Author(s): Kamalika Sen, Dhananjay Bhattacharyya, Arijita Sarkar, Jyotirmoy Das, Nilanjana Maji, Moitri Basu, Zhumur Ghosh, Tapash Chandra GhoshAbstractBackgroundHuman Chronic and Acute Myeloid Leukemia are myeloproliferative disorders in myeloid lineage of blood cells characterized by accumulation of aberrant white blood cells. In cancer, the anomalous transcriptome includes deregulated expression of non-coding RNAs in conjunction with protein-coding mRNAs in human genome. The coding or non-coding RNA transc…

ke Verbeek

Treatment options for older patients with intermediate or high-risk acute myeloid leukemia (AML) remain unsatisfactory. Allogeneic stem cell transplantation, the treatment of choice for the majority of younger AML patients, has been hampered in elderly patients by higher treatment related mortality, comorbidities and lack of a suitable donor. With the higher availability of suitable donors as well as of reduced intensity conditioning regimens, novel low intensity treatments prior to transplantation and optimized supportive care, the number of older AML patients being successfully transplanted is steadily inc…

Source: CancersCategory: Cancer & Oncology Authors: Tags: Review Source Type: research

Targeted therapy has always been the focus in developing therapeutic approaches in cancer, especially in the treatment of acute myeloid leukemia (AML). A new small molecular inhibitor, JQ1, targeting BRD4, whi…

Source: BMC CancerCategory: Cancer & Oncology Authors: Tags: Research article Source Type: research

The original article [1] contained minor typesetting errors affecting the following authors: Ziang Jeff Gao, Xiao Zhen Zhou, and Kun Ping Lu.

Source: Journal of Hematology and OncologyCategory: Hematology Authors: Tags: Correction Source Type: research

ConclusionsOur findings indicated that lower expression of BM miR-122 acted as an independent risk factor for OS in CN-AML.

Publication date: September 2018Source: Human Pathology: Case Reports, Volume 13Author(s): Emily Feldpausch, Shilpa Sambidi, Durga Cherukuri, Jagmohan SidhuAbstractThe myeloproliferative neoplasms (MPNs) are chronic myeloid cancers (clonal hematopoietic disorders) that are characterized by the overproduction of terminally differentiated (mature) blood cells, and that may evolve into acute myeloid leukemia (AML). The literature indicates that three known driver mutations currently exist in BCR/ABL1-negative MPNs: JAK2, MPL and CALR. A small percentage of BCR/ABL1-negative MPN cases lack mutations in all three of these genes…

Publication date: 2018Source: Leukemia Research Reports, Volume 9Author(s): Gina Ma, Yi Wang, Tahmeena Ahmed, Ann-Leslie Zaslav, Laura Hogan, Cecilia Avila, Masayuki Wada, Huda SalmanAbstractAberrant expression of CD19 in acute myeloid leukemia (AML) is commonly associated with t(8;21)(q22;q22), although AML cases lacking this translocation occasionally express CD19. Mixed-phenotype acute leukemia also frequently expresses CD19. Chimeric antigen receptor (CAR) technology is a major breakthrough for cancer treatment, with the recent approval of CD19-directed CAR (CD19CAR) for treating B-cell malignancies. However, little in…

Publication date: August 2018Source: Hematology/Oncology Clinics of North America, Volume 32, Issue 4Author(s): Sharon A. Savage, Michael F. Walsh





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here